Proservice Bldg Regulatory News (PRO)

10 Nov 2005 07:00

Provalis PLC10 November 2005 10 November 2005 Provalis plcAnnual Information Update 2005 Provalis plc ("the Company") is pleased to provide its' annual informationupdate, in accordance with the requirements of the Prospectus Rule 5.2. Thisupdate refers to information that has been published or made available by theCompany to the public over the twelve months ending today. To avoid anunnecessarily lengthy document, information is referred to in this update ratherthan included in full. The information referred to in this update was up to date at the time theinformation was published but some information may now be out-of-date. (1) Announcements made via RNS, a Regulatory Information Service All of the documents listed below were published via RNS, a RegulatoryInformation Service on or around the dates indicated. Date of publication Brief description of announcement 19/10/2005 Preliminary Results13/09/2005 Notice of Preliminary Results10/08/2005 Board Change03/08/2005 NGSP Certification for in2it(TM)A1C26/07/2005 Update on progress of in2it(TM)A1C10/06/2005 Appointment of director10/06/2005 Trading Update01/04/2005 Retirement of director02/03/2005 Director Shareholding01/03/2005 Interim Results25/02/2005 Intention to terminate US Listing18/02/2005 Board Changes25/01/2005 Notice of Interim Results07/01/2005 Half Year Trading Update13/12/2004 Vaccine Option Agreement03/12/2004 First Commercial Shipment of in2it(TM)A1C22/11/2004 Final Payment for Diclomax Copies of the above announcements can be downloaded from the Company's website(www.provalis.com) or obtained from the Company Secretary at the Company'sRegistered Office, Newtech Square, Deeside Industrial Park, Deeside, Flintshire,CH5 2NT. (2) Documents filed at Companies House All of the documents listed below were filed with Companies House in Cardiff onor around the dates indicated. Date of filing Brief description of document 13/09/05 Form 403A Declaration of satisfaction in full of guarantee and debenture in favour of Barclays Bank plc06/09/05 Form 288b relating to the resignation of Dr Philip Gould as a director01/07/05 Form 288a relating to the appointment of Peter Woodford as a director04/04/05 Form 288b relating to the resignation of Dr David Bloxham as a director23/03/05 Form 363s Annual Return22/02/05 Form 288a relating to appointment of Dr Alan Aikman as a director9/11/04 Annual Report and Accounts 2004 Copies of documents filed at Companies House can be obtained from CompaniesHouse or from the Company Secretary at the Company's Registered Office, NewtechSquare, Deeside Industrial Park, Deeside, Flintshire, CH5 2NT. Contacts: Provalis plc 01244 833 402Lee Greenbury, Company Secretary College Hill 0207 457 2020Adrian Dufield/ Corinna Dorward "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Statements in this announcement that relate to future plans, expectations,events, performances and the like are forward-looking statements as defined inthe US Private Securities Litigation Reform Act of 1995. Actual results ofevents could differ materially from those described in the forward-lookingstatements due to a variety of factors. Such factors include, among others: theviability of the Group's products, which are at various stages of development;the generation of sufficient operating cash flow by the Group's pharmaceuticaland medical diagnostic businesses to finance the ongoing development of thesebusinesses as well as the Group's research and development activities; thesuccess of the Group's research and development strategy and activities;uncertainties related to future clinical trial results and the associatedregulatory process; the execution and success of collaborative agreements withthird parties; availability and level of reimbursement for the Group's productsfrom government health administration authorities or other third-party payors;the rate of net cash utilisation within the Group and, hence, the Group'spossible need for additional capital in the short, medium and/or long term; theGroup's intellectual property position and the success of patent applicationsfor its products and technologies; the Group's dependence on key personnel;general business and economic conditions; the impact of future laws, regulationsand policies; stock market trends in the Group's sector; and other factorsbeyond the Group's control that may cause the Group's available capitalresources to be used more quickly than expected. These and other factors thatcould affect the Company's future results are more fully described in itsfilings with the US Securities and Exchange Commission, in particular the latest20-F filing, copies of which are available from the Company Secretary at theCompany's registered address. This information is provided by RNS The company news service from the London Stock Exchange